Market Overview

Deutsche Bank Reiterates On Medtronic And Covidien Amid Acquisition Proposal

Share:
Related MDT
Earnings Scheduled For February 21, 2017
DexCom Jumps 25% As It Becomes Only Continuous Glucose Monitoring With Medicare Coverage

In a note released Tuesday morning, Deutsche Bank analyst Kristen Stewart reiterated a Buy rating on both Medtronic (NYSE: MDT) and Covidien plc (NYSE: COV) and raised her price targets from $74.00 to $85.00 and from $93.00 to $114.00, respectively.

The change in price target comes amid a proposed acquisition of Covidien by Medtronic, which Stewart is saying has a "high likelihood" of closing.

Stewart wrote, "We believe the whole is greater than the sum-of-the-parts. Medtronic plc will be a stronger, better positioned company and a more attractive investment for investors."

In terms of synergies, Stewart noted that she believes the target cost synergy of at least $850 million is "just that (at least)" and said that, although management has not made any projections for revenue synergies, she believes there will be such synergies in both the near- and long-term.

Latest Ratings for MDT

DateFirmActionFromTo
Jan 2017JP MorganDowngradesOverweightNeutral
Jan 2017Morgan StanleyDowngradesOverweightEqual-Weight
Nov 2016OppenheimerMaintainsOutperform

View More Analyst Ratings for MDT
View the Latest Analyst Ratings

Posted-In: Deutsche Bank Kristen StewartAnalyst Color Price Target Reiteration M&A Analyst Ratings

 

Related Articles (COV + MDT)

View Comments and Join the Discussion!